This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ReNeuron Group Temettü

Temettü kriter kontrolleri 0/6

ReNeuron Group şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.05%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.05%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: RENE şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: RENE şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

ReNeuron Group Piyasaya Karşı Temettü Getirisi

RENE temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (RENE)	n/a
Pazarın Alt %25'i (GB)	2.1%
Pazarın En İyi %25'i (GB)	5.7%
Sektör Ortalaması (Biotechs)	1.5%
Analist tahmini (RENE) (3 yıla kadar)	0%

Önemli Temettü: RENE şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, RENE şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: RENE şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: RENE herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

This company listing is no longer active

ReNeuron Group Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024

ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024

ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024

Consensus revenue estimates decrease by 28%, EPS upgraded

New minor risk - Profitability

ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023

ReNeuron Group plc, Annual General Meeting, Aug 22, 2023

Consensus EPS estimates upgraded to UK£0.10 loss

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReNeuron Group plc to Report Q4, 2023 Results on May 25, 2023

High number of new and inexperienced directors

ReNeuron Group plc Appoints Iain Ross as Executive Chairman

Consensus forecasts updated

First half 2023 earnings released: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022)

No longer forecast to breakeven

Less than half of directors are independent

Less than half of directors are independent

ReNeuron Group plc Appoints John Hawkins as Chief Financial Officer

Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)

ReNeuron Group plc, Annual General Meeting, Sep 09, 2022

ReNeuron Group plc, Annual General Meeting, Sep 09, 2022

ReNeuron Group plc Announces Appointment of Catherine Isted as Chief Executive Officer, Effective 1 September 2022

We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth Carefully

Price target decreased to UK£2.22

Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)

ReNeuron Group plc to Report Fiscal Year 2022 Results on Jul 04, 2022

Price target decreased to UK£2.19

ReNeuron Group plc, Annual General Meeting, Jul 14, 2022

Price target decreased to UK£2.04

ReNeuron Group plc Announces CEO Changes, Effective 28 February 2022

ReNeuron Group plc Announces Leaving of Olav Hellebø as Executive Director

We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn Rate

Price target decreased to UK£2.04

First half 2022 earnings: EPS and revenues miss analyst expectations

Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth

Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)

Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)

Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?

ReNeuron Group plc Announces Resignation of Michael Hunt, Chief Financial Officer

Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?

New 90-day high: UK£1.11

New 90-day low: UK£0.72

First half 2021 earnings released: UK£0.22 loss per share

New 90-day low: UK£0.78

Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)

ReNeuron Group plc to Report First Half, 2021 Results on Nov 10, 2020

New 90-day low: UK£0.85

Analysts update estimates

ReNeuron Group plc Auditor Raises 'Going Concern' Doubt

Full year earnings released - UK£0.36 loss per share

New 90-day low - UK£1.08

New 90-day low - UK£1.22

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin